Prostate Cancer:@0.762090:0.035749:0.914561:0.035749:0.914561:0.019993:0.762090:0.019993:0.011392:0.005709:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
61:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Dr PW van Zijl:@0.084848:0.150332:0.207615:0.150332:0.207615:0.134299:0.084848:0.134299:0.013470:0.006158:0.005388:0.010776:0.017318:0.005388:0.010776:0.012700:0.011545:0.005388:0.009621:0.004618:0.005003:0.004618
MBChB, MMed, FC Rad Onc:@0.084848:0.166578:0.343851:0.166578:0.343851:0.150359:0.084848:0.150359:0.017318:0.011161:0.015009:0.011545:0.011161:0.005388:0.005388:0.017318:0.017318:0.012315:0.012700:0.005388:0.005388:0.009236:0.015009:0.005388:0.011161:0.012700:0.012700:0.005388:0.016164:0.011545:0.012315
 :@0.084848:0.182704:0.121236:0.182704:0.121236:0.168020:0.084848:0.168020:0.017145:0.019242
Clinical and Radiation Oncologist :@0.121236:0.182823:0.439447:0.182823:0.439447:0.167067:0.121236:0.167067:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.013143:0.011738:0.013181:0.005330:0.011680:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.016722:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.005330
in private practice, Life Wilgers Hospital, :@0.084848:0.199069:0.458482:0.199069:0.458482:0.183313:0.084848:0.183313:0.003848:0.011738:0.005330:0.013123:0.005792:0.003848:0.010660:0.013143:0.006523:0.012508:0.005330:0.013123:0.005792:0.013143:0.012450:0.006523:0.003848:0.012450:0.012508:0.005330:0.005330:0.008890:0.003848:0.006042:0.012508:0.005330:0.018573:0.003848:0.003848:0.012950:0.012508:0.005792:0.007466:0.005330:0.013143:0.012604:0.007466:0.013123:0.003848:0.006523:0.013143:0.003848:0.005330:0.005330
Pretoria:@0.084848:0.215314:0.156367:0.215314:0.156367:0.199558:0.084848:0.199558:0.011392:0.005709:0.012508:0.006523:0.012604:0.005792:0.003848:0.013143
Second to lung cancer, prostate cancer :@0.084848:0.247818:0.481101:0.247818:0.481101:0.232062:0.084848:0.232062:0.009583:0.012508:0.012450:0.012604:0.011738:0.013181:0.008486:0.006523:0.012604:0.008486:0.003848:0.011699:0.011738:0.012950:0.008486:0.012450:0.013143:0.011738:0.012450:0.012508:0.003766:0.005330:0.008486:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.008486:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
is the most commonly diagnosed cancer :@0.084848:0.264063:0.481107:0.264063:0.481107:0.248307:0.084848:0.248307:0.003848:0.007466:0.007177:0.006523:0.011738:0.012508:0.007160:0.018049:0.012604:0.007466:0.006523:0.007166:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.003848:0.010314:0.007168:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.013181:0.007177:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
in men 50 years and older. This is true for :@0.084848:0.280309:0.481123:0.280309:0.481123:0.264553:0.084848:0.264553:0.003848:0.011738:0.007678:0.018049:0.012508:0.011738:0.007678:0.010660:0.010660:0.007678:0.010314:0.012508:0.013143:0.005792:0.007466:0.007678:0.013143:0.011738:0.013181:0.007678:0.012604:0.003848:0.013181:0.012508:0.004378:0.005330:0.007678:0.008197:0.011738:0.003848:0.007466:0.007678:0.003848:0.007466:0.007678:0.006523:0.005792:0.011699:0.012508:0.007664:0.006042:0.012604:0.005792:0.005330
developed countries as well as develop-:@0.084848:0.296554:0.475744:0.296554:0.475744:0.280798:0.084848:0.280798:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.012508:0.013181:0.007986:0.012450:0.012604:0.011699:0.011738:0.006523:0.005792:0.003848:0.012508:0.007466:0.007972:0.013143:0.007466:0.007986:0.015990:0.012508:0.003848:0.003848:0.007986:0.013143:0.007466:0.007986:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.006388
ing countries.  In the USA, the incidence of :@0.084848:0.312800:0.481105:0.312839:0.481105:0.297083:0.084848:0.297044:0.003848:0.011738:0.012950:0.004849:0.012450:0.012604:0.011699:0.011738:0.006523:0.005792:0.003848:0.012508:0.007466:0.005330:0.006203:0.004849:0.004349:0.011738:0.004849:0.006523:0.011738:0.012508:0.004849:0.012604:0.009583:0.014239:0.005330:0.004839:0.006523:0.011738:0.012508:0.004849:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.004849:0.012604:0.006042:0.546649
1:@0.208178:0.307220:0.214393:0.307220:0.214393:0.298034:0.208178:0.298034:0.006215
prostate cancer is 160 per 100 000.:@0.084856:0.329084:0.406531:0.329084:0.406531:0.313328:0.084856:0.313328:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.003848:0.007466:0.005330:0.010660:0.010660:0.010660:0.005330:0.013123:0.012508:0.005792:0.005330:0.010660:0.010660:0.010660:0.005330:0.010660:0.010660:0.010660:0.005330
2:@0.406529:0.323471:0.412744:0.323471:0.412744:0.314285:0.406529:0.314285:0.006215
IMPACT ON SOCIETY:@0.084848:0.362238:0.315330:0.362238:0.315330:0.342641:0.084848:0.342641:0.006585:0.021167:0.013170:0.017404:0.018344:0.009878:0.006585:0.019756:0.017404:0.006585:0.012230:0.019756:0.018344:0.006585:0.012230:0.009878:0.014581
Until 2004, the development of castration-:@0.084848:0.380781:0.475769:0.380781:0.475769:0.365025:0.084848:0.365025:0.012604:0.011738:0.006523:0.003848:0.003848:0.005619:0.010660:0.010660:0.010672:0.010660:0.005330:0.005619:0.006523:0.011738:0.012508:0.005619:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.005619:0.012604:0.006042:0.005619:0.012450:0.013143:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.006388
resistant prostate cancer was a uniformly :@0.084848:0.397027:0.481073:0.397027:0.481073:0.381271:0.084848:0.381271:0.005713:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.007216:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.007216:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007216:0.015990:0.013143:0.007466:0.007216:0.013143:0.007216:0.011699:0.011738:0.003848:0.006042:0.012604:0.006317:0.018049:0.003848:0.010314:0.005330
lethal event. These patients mostly devel-:@0.084848:0.413272:0.475739:0.413272:0.475739:0.397516:0.084848:0.397516:0.003848:0.012508:0.006523:0.011738:0.013143:0.003848:0.006966:0.012508:0.010660:0.012508:0.011738:0.006523:0.005330:0.006966:0.008197:0.011738:0.012508:0.007466:0.012508:0.006966:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006966:0.018049:0.012604:0.007466:0.006523:0.003848:0.010314:0.006966:0.013181:0.012508:0.010660:0.012508:0.003848:0.006388
oped  skeletal-related  events.  Docetaxel, :@0.084848:0.429518:0.481096:0.429518:0.481096:0.413762:0.084848:0.413762:0.012604:0.013123:0.012508:0.013181:0.005330:0.003662:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.006388:0.005719:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.003666:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330:0.003664:0.014316:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.005330
which prolonged survival, and zoledronic :@0.084848:0.445763:0.481096:0.445763:0.481096:0.430007:0.084848:0.430007:0.015990:0.011738:0.003848:0.012450:0.011738:0.007428:0.013123:0.005711:0.012604:0.003848:0.012604:0.011738:0.012950:0.012496:0.013181:0.007428:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.007439:0.013143:0.011738:0.013181:0.007428:0.008178:0.012604:0.003848:0.012508:0.013181:0.005707:0.012604:0.011738:0.003848:0.012450:0.005330
acid, a bisphosphonate, which delays the :@0.084848:0.462008:0.481074:0.462008:0.481074:0.446253:0.084848:0.446253:0.013143:0.012450:0.003848:0.013181:0.005330:0.005349:0.013143:0.005349:0.013123:0.003848:0.007466:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.012604:0.011738:0.013143:0.006523:0.012508:0.005330:0.005336:0.015990:0.011738:0.003848:0.012450:0.011738:0.005349:0.013181:0.012508:0.003848:0.013143:0.010314:0.007466:0.005349:0.006523:0.011738:0.012508:0.005330
progression of skeletal-related events had :@0.084848:0.478254:0.481096:0.478254:0.481096:0.462498:0.084848:0.462498:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005946:0.012604:0.006042:0.005934:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.006388:0.005715:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005946:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005936:0.011738:0.013143:0.013181:0.005330
a significant impact on the disease. Since :@0.084848:0.494499:0.481076:0.494499:0.481076:0.478743:0.084848:0.478743:0.013143:0.006146:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.006140:0.003848:0.018049:0.013123:0.013143:0.012450:0.006523:0.006146:0.012604:0.011738:0.006138:0.006523:0.011738:0.012508:0.006138:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.006148:0.009583:0.003848:0.011738:0.012450:0.012508:0.005330
then, findings demonstrating the benefit of :@0.084848:0.510745:0.481098:0.510745:0.481098:0.494989:0.084848:0.494989:0.006523:0.011738:0.012508:0.011738:0.005330:0.004305:0.004686:0.004686:0.011738:0.013181:0.003848:0.011738:0.012950:0.007466:0.004312:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.011738:0.012950:0.004305:0.006523:0.011738:0.012508:0.004314:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.004306:0.012604:0.006042:0.005330
early chemotherapy together with three :@0.084848:0.526990:0.481107:0.526990:0.481107:0.511234:0.084848:0.511234:0.012508:0.013143:0.005792:0.003848:0.010314:0.009159:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011726:0.012508:0.005792:0.013143:0.013123:0.010314:0.009159:0.006523:0.012604:0.012950:0.012508:0.006523:0.011738:0.012488:0.005792:0.009159:0.015990:0.003848:0.006523:0.011738:0.009159:0.006523:0.011738:0.005707:0.012508:0.012508:0.005330
new  drugs  have  added to  our  ability to :@0.084848:0.543236:0.481103:0.543236:0.481103:0.527480:0.084848:0.527480:0.011738:0.012508:0.015990:0.005330:0.003718:0.013181:0.005792:0.011699:0.012950:0.007466:0.005330:0.003721:0.011738:0.013143:0.010660:0.012508:0.005330:0.003718:0.013143:0.013181:0.013181:0.012508:0.013181:0.009063:0.006523:0.012604:0.005330:0.003714:0.012604:0.011699:0.005792:0.005330:0.003714:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.009063:0.006523:0.012604:0.005330
curb the impact.:@0.084848:0.559481:0.241809:0.559481:0.241809:0.543725:0.084848:0.543725:0.012450:0.011699:0.005792:0.013123:0.005330:0.006523:0.011738:0.012508:0.005330:0.003848:0.018049:0.013123:0.013143:0.012450:0.006523:0.005330
During the last decades, mortality rates :@0.103032:0.575726:0.481130:0.575726:0.481130:0.559970:0.103032:0.559970:0.014124:0.011507:0.005600:0.003656:0.011545:0.012758:0.008274:0.006331:0.011545:0.012315:0.008274:0.003656:0.012950:0.007274:0.006331:0.008274:0.012989:0.012315:0.012257:0.012950:0.012989:0.012315:0.007274:0.005138:0.008274:0.017857:0.012411:0.005600:0.006331:0.012950:0.003656:0.003656:0.006331:0.010122:0.008274:0.005600:0.012950:0.006331:0.012315:0.007470:0.005330
have declined sharply, mainly because of :@0.084848:0.591972:0.481088:0.591972:0.481088:0.576216:0.084848:0.576216:0.011545:0.012950:0.010468:0.012315:0.006581:0.012989:0.012315:0.012257:0.003656:0.003656:0.011545:0.012315:0.012989:0.006581:0.007274:0.011545:0.012950:0.005600:0.012931:0.003656:0.010122:0.005138:0.006581:0.017857:0.012950:0.003656:0.011545:0.003656:0.010122:0.006581:0.012931:0.012315:0.012257:0.012950:0.011507:0.007274:0.012315:0.006581:0.012411:0.006042:0.005330
improved treatments and earlier diagnosis.:@0.084848:0.608217:0.475735:0.608217:0.475735:0.592461:0.084848:0.592461:0.003656:0.017857:0.012931:0.005521:0.012411:0.010468:0.012315:0.012989:0.005138:0.006331:0.005521:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.007274:0.005138:0.012950:0.011545:0.012989:0.005138:0.012315:0.012950:0.005600:0.003656:0.003656:0.012315:0.005600:0.005138:0.012989:0.003656:0.012950:0.012758:0.011545:0.012411:0.007274:0.003656:0.007274:0.005330
It is not only mortality, but morbidity, lack :@0.103032:0.624463:0.481111:0.624463:0.481111:0.608707:0.103032:0.608707:0.004349:0.006523:0.004599:0.003848:0.007466:0.004599:0.011738:0.012604:0.006523:0.004585:0.012604:0.011738:0.003848:0.010314:0.004599:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.004587:0.013123:0.011699:0.006523:0.004589:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.010314:0.005330:0.004599:0.003848:0.013143:0.012450:0.009660:0.005330
of  productivity (in younger  working-age :@0.084848:0.640708:0.481096:0.640708:0.481096:0.624952:0.084848:0.624952:0.012604:0.006042:0.005330:0.005648:0.013123:0.005711:0.012604:0.013181:0.011699:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.010987:0.007100:0.003848:0.011738:0.010987:0.010314:0.012604:0.011699:0.011738:0.012950:0.012508:0.005792:0.005330:0.005640:0.015990:0.012604:0.005792:0.009660:0.003848:0.011738:0.012950:0.006388:0.013143:0.012950:0.012508:0.005330
men)  and  the  financial  burden  of  costly :@0.084848:0.656953:0.481080:0.656953:0.481080:0.641198:0.084848:0.641198:0.018049:0.012508:0.011738:0.007100:0.005330:0.003608:0.013143:0.011738:0.013181:0.005330:0.003608:0.006523:0.011738:0.012508:0.005330:0.003604:0.004686:0.004686:0.011738:0.013143:0.011738:0.012450:0.003848:0.013143:0.003848:0.005330:0.003612:0.013123:0.011699:0.005675:0.013181:0.012508:0.011738:0.005330:0.003606:0.012604:0.006042:0.005330:0.003604:0.012450:0.012604:0.007466:0.006523:0.003848:0.010314:0.005330
treatment that impact on society.:@0.084848:0.673199:0.399841:0.673199:0.399841:0.657443:0.084848:0.657443:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.003848:0.018049:0.013123:0.013143:0.012450:0.006523:0.005330:0.012604:0.011738:0.005330:0.007466:0.012604:0.012450:0.003848:0.012508:0.006523:0.010314:0.005330
DIAGNOSTIC ISSUES:@0.084848:0.706441:0.306393:0.706441:0.306393:0.686845:0.084848:0.686845:0.016463:0.006585:0.017404:0.019756:0.017404:0.019756:0.012230:0.009878:0.006585:0.018344:0.006585:0.006585:0.012230:0.012230:0.015052:0.012230:0.012230
A number of methods are used in the di-:@0.084848:0.724985:0.475783:0.724985:0.475783:0.709229:0.084848:0.709229:0.014239:0.007139:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.007129:0.012604:0.006042:0.007139:0.018049:0.012508:0.006523:0.011738:0.012604:0.013181:0.007466:0.007127:0.013143:0.005715:0.012508:0.007139:0.011699:0.007466:0.012508:0.013181:0.007139:0.003848:0.011738:0.007139:0.006523:0.011738:0.012508:0.007127:0.013181:0.003848:0.006388
agnosis of prostate cancers and there are :@0.084848:0.741230:0.481117:0.741230:0.481117:0.725475:0.084848:0.725475:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005253:0.012604:0.006042:0.005253:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005253:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005253:0.013143:0.011738:0.013181:0.005253:0.006523:0.011738:0.012508:0.005705:0.012508:0.005253:0.013143:0.005715:0.012508:0.005330
several diagnostic issues to consider. :@0.084848:0.757476:0.428258:0.757476:0.428258:0.741720:0.084848:0.741720:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.005330:0.003848:0.007466:0.007466:0.011699:0.012508:0.007466:0.005330:0.006523:0.012604:0.005330:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.004378:0.005330:0.005330
These include::@0.084848:0.789980:0.217198:0.789980:0.217198:0.774224:0.084848:0.774224:0.008197:0.011738:0.012508:0.007466:0.012508:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
n   :@0.084848:0.803119:0.107657:0.803119:0.107657:0.794679:0.084848:0.794679:0.009762:0.003566:0.005914:0.003566
PSA :@0.104091:0.806238:0.144500:0.806238:0.144500:0.790205:0.104091:0.790205:0.010776:0.010006:0.014239:0.005388
– Prostatic-specific antigen (PSA) :@0.144500:0.806238:0.454562:0.806238:0.454562:0.790482:0.144500:0.790482:0.009621:0.005330:0.011392:0.005705:0.012604:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.005330:0.007100:0.011392:0.009583:0.014239:0.007100:0.005330
for adenocarcinomas of the prostate:@0.104091:0.822484:0.450554:0.822484:0.450554:0.806728:0.104091:0.806728:0.006042:0.012604:0.005792:0.005330:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005640:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.007466:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.013123:0.005698:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508
n   :@0.084848:0.835621:0.107657:0.835621:0.107657:0.827180:0.084848:0.827180:0.009762:0.003566:0.005914:0.003566
DRE :@0.104091:0.838740:0.144115:0.838740:0.144115:0.822706:0.104091:0.822706:0.013470:0.011161:0.010006:0.005388
– Digital rectal examination (DRE):@0.144115:0.838740:0.454612:0.838740:0.454612:0.822984:0.144115:0.822984:0.009621:0.005330:0.014316:0.003848:0.012950:0.003848:0.006523:0.013143:0.003848:0.005330:0.005717:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.012508:0.009236:0.013143:0.018049:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.007100:0.014316:0.011680:0.010314:0.007100
n   :@0.084848:0.851871:0.107657:0.851871:0.107657:0.843431:0.084848:0.843431:0.009762:0.003566:0.005914:0.003566
TRUS :@0.104091:0.854990:0.151042:0.854990:0.151042:0.838957:0.104091:0.838957:0.008082:0.011161:0.012315:0.010006:0.005388
– Transrectal ultrasound (TRUS) and :@0.151042:0.854990:0.479273:0.854990:0.479273:0.839234:0.151042:0.839234:0.009621:0.005330:0.007618:0.005792:0.013143:0.011738:0.007466:0.005711:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.011699:0.003848:0.006523:0.005792:0.013143:0.007466:0.012604:0.011699:0.011738:0.013181:0.005330:0.007100:0.008197:0.011680:0.012604:0.009583:0.007100:0.005330:0.013143:0.011738:0.013181:0.005330
biopsy.:@0.104091:0.871236:0.169900:0.871236:0.169900:0.855480:0.104091:0.855480:0.013123:0.003848:0.012604:0.013123:0.007466:0.010314:0.005330
Compared to DRE, the appropriate use of :@0.084848:0.903740:0.481090:0.903740:0.481090:0.887984:0.084848:0.887984:0.015644:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005407:0.006523:0.012604:0.005407:0.014316:0.011680:0.010314:0.005330:0.005407:0.006523:0.011738:0.012508:0.005407:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005407:0.011699:0.007466:0.012508:0.005407:0.012604:0.006042:0.005330
PSA alone can give a diagnostic advan-:@0.084848:0.919985:0.475762:0.919985:0.475762:0.904229:0.084848:0.904229:0.011392:0.009583:0.014239:0.007560:0.013143:0.003848:0.012604:0.011738:0.012508:0.007564:0.012450:0.013143:0.011738:0.007568:0.012950:0.003848:0.010660:0.012508:0.007572:0.013143:0.007570:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.007582:0.013143:0.013181:0.010660:0.013143:0.011738:0.006388
tage of five to 10 years. PSA levels of more :@0.084848:0.936231:0.481090:0.936231:0.481090:0.920475:0.084848:0.920475:0.006523:0.013143:0.012950:0.012508:0.005111:0.012604:0.006042:0.005113:0.004686:0.004686:0.010660:0.012508:0.005115:0.006523:0.012604:0.005109:0.010660:0.010660:0.005124:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.005117:0.011392:0.009583:0.014239:0.005109:0.003848:0.012508:0.010660:0.012508:0.003848:0.007466:0.005128:0.012604:0.006042:0.005111:0.018049:0.012604:0.005709:0.012508:0.005330
than 4 ng/ml lead to an approximate 30-:@0.524249:0.150326:0.915160:0.150326:0.915160:0.134570:0.524249:0.134570:0.006523:0.011738:0.013143:0.011738:0.006666:0.010660:0.006677:0.011738:0.012950:0.008409:0.018049:0.003848:0.006677:0.003848:0.012508:0.013143:0.013181:0.006677:0.006523:0.012604:0.006664:0.013143:0.011738:0.006677:0.013143:0.013123:0.013123:0.005713:0.012604:0.009236:0.003848:0.018049:0.013143:0.006523:0.012508:0.006667:0.010660:0.010660:0.006388
35% increase in the likelihood of detecting :@0.524249:0.166611:0.920479:0.166611:0.920479:0.150855:0.524249:0.150855:0.010660:0.010660:0.014913:0.005072:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.005061:0.003848:0.011738:0.005061:0.006523:0.011738:0.012508:0.005061:0.003848:0.003848:0.009660:0.012508:0.003848:0.003848:0.011738:0.012604:0.012604:0.013181:0.005061:0.012604:0.006042:0.005061:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.003848:0.011738:0.012950:0.005330
prostate cancer at prostate biopsy. Men :@0.524249:0.182896:0.920500:0.182896:0.920500:0.167140:0.524249:0.167140:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.008043:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.008043:0.013143:0.006523:0.008043:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.008043:0.013123:0.003848:0.012604:0.013123:0.007466:0.010314:0.005330:0.008055:0.017684:0.012508:0.011738:0.005330
with this level should be encouraged  to :@0.524249:0.199181:0.920479:0.199181:0.920479:0.183425:0.524249:0.183425:0.015990:0.003848:0.006523:0.011738:0.009333:0.006523:0.011738:0.003848:0.007466:0.009333:0.003848:0.012508:0.010660:0.012508:0.003848:0.009333:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.009333:0.013123:0.012508:0.009333:0.012508:0.011738:0.012450:0.012604:0.011699:0.005792:0.013143:0.012950:0.012508:0.013181:0.005330:0.003993:0.006523:0.012604:0.005330
undergo TRUS-guided biopsy.:@0.524249:0.215466:0.797010:0.215466:0.797010:0.199710:0.524249:0.199710:0.011699:0.011738:0.013181:0.012508:0.005792:0.012950:0.012604:0.005330:0.008197:0.011680:0.012604:0.009583:0.006388:0.012950:0.011699:0.003848:0.013181:0.012508:0.013181:0.005330:0.013123:0.003848:0.012604:0.013123:0.007466:0.010314:0.005330
n   :@0.524242:0.228620:0.547050:0.228620:0.547050:0.220179:0.524242:0.220179:0.009762:0.003566:0.005914:0.003566
PSA velocity and free fraction :@0.543484:0.231739:0.823269:0.231739:0.823269:0.215705:0.543484:0.215705:0.010776:0.010006:0.014239:0.005388:0.010776:0.012315:0.004618:0.012315:0.012315:0.004618:0.005773:0.011161:0.005388:0.012700:0.011545:0.012700:0.005388:0.005388:0.006158:0.012315:0.012315:0.005388:0.005388:0.006158:0.012700:0.012315:0.005773:0.004618:0.012315:0.011545:0.005388
– :@0.823250:0.231739:0.838201:0.231739:0.838201:0.215983:0.823250:0.215983:0.009621:0.005330
velocity is the increase of PSA values :@0.543484:0.248024:0.888187:0.248024:0.888187:0.232268:0.543484:0.232268:0.010660:0.012508:0.003848:0.012604:0.012450:0.003848:0.006523:0.010314:0.005330:0.003848:0.007466:0.005330:0.006523:0.011738:0.012508:0.005330:0.003848:0.011738:0.012450:0.005709:0.012508:0.013143:0.007466:0.012508:0.005330:0.012604:0.006042:0.005330:0.011392:0.009583:0.014239:0.005330:0.010660:0.013143:0.003848:0.011699:0.012508:0.007466:0.005330
over time. A cut-off of 0.75 ng/ml per :@0.543484:0.264309:0.892336:0.264309:0.892336:0.248553:0.543484:0.248553:0.012604:0.010660:0.012508:0.005792:0.005330:0.006523:0.003848:0.018049:0.012508:0.005330:0.005330:0.014239:0.005330:0.012450:0.011699:0.006523:0.006388:0.012604:0.006067:0.006042:0.005330:0.012604:0.006042:0.005330:0.010660:0.005330:0.010660:0.010660:0.005330:0.011738:0.012950:0.008409:0.018049:0.003848:0.005330:0.013123:0.012508:0.005792:0.005330
year increases the sensitivity of PSA :@0.543484:0.280594:0.873428:0.280594:0.873428:0.264838:0.543484:0.264838:0.010314:0.012508:0.013143:0.005792:0.005330:0.003848:0.011738:0.012450:0.005709:0.012508:0.013143:0.007466:0.012508:0.007466:0.005330:0.006523:0.011738:0.012508:0.005330:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330:0.012604:0.006042:0.005330:0.011392:0.009583:0.014239:0.005330
testing alone. It is recommended :@0.543484:0.296879:0.855519:0.296879:0.855519:0.281123:0.543484:0.281123:0.006523:0.012508:0.007466:0.006523:0.003848:0.011738:0.012950:0.005330:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.005330:0.004349:0.006523:0.005330:0.003848:0.007466:0.005330:0.005696:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.012508:0.013181:0.005330
that three levels of PSA be obtained :@0.543484:0.313164:0.884694:0.313164:0.884694:0.297408:0.543484:0.297408:0.006523:0.011738:0.013143:0.006523:0.005330:0.006523:0.011738:0.005700:0.012508:0.012508:0.005330:0.003848:0.012508:0.010660:0.012508:0.003848:0.007466:0.005330:0.012604:0.006042:0.005330:0.011392:0.009583:0.014239:0.005330:0.013123:0.012508:0.005330:0.012604:0.013123:0.006523:0.013143:0.003848:0.011738:0.012508:0.013181:0.005330
over an 18-month period. Free PSA is :@0.543484:0.329449:0.888545:0.329449:0.888545:0.313694:0.543484:0.313694:0.012604:0.010660:0.012508:0.005792:0.005330:0.013143:0.011738:0.005330:0.010660:0.010660:0.006388:0.018049:0.012604:0.011738:0.006523:0.011738:0.005330:0.013123:0.012508:0.005792:0.003848:0.012604:0.013181:0.005330:0.005330:0.009333:0.005682:0.012508:0.012508:0.005330:0.011392:0.009583:0.014239:0.005330:0.003848:0.007466:0.005330
significantly lower in men who have :@0.543484:0.345735:0.879707:0.345735:0.879707:0.329979:0.543484:0.329979:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.003848:0.012604:0.015990:0.012508:0.005792:0.005330:0.003848:0.011738:0.005330:0.018049:0.012508:0.011738:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330
prostate cancer compared with men :@0.543484:0.362020:0.896965:0.362020:0.896965:0.346264:0.543484:0.346264:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.012450:0.012604:0.018049:0.013123:0.013143:0.005694:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.018049:0.012508:0.011738:0.005330
who do not have prostate cancer. :@0.543484:0.378305:0.870057:0.378305:0.870057:0.362549:0.543484:0.362549:0.015990:0.011738:0.012604:0.005330:0.013181:0.012604:0.005330:0.011738:0.012604:0.006523:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.013123:0.005688:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.004366:0.005330:0.005330
A free PSA level of 25% and below :@0.543484:0.394590:0.866726:0.394590:0.866726:0.378834:0.543484:0.378834:0.014239:0.005330:0.006042:0.005703:0.012508:0.012508:0.005330:0.011392:0.009583:0.014239:0.005330:0.003848:0.012508:0.010660:0.012508:0.003848:0.005330:0.012604:0.006042:0.005330:0.010660:0.010660:0.014913:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.012508:0.003848:0.012604:0.015990:0.005330
in patients with a PSA of 4-10 ng/ml :@0.543484:0.410875:0.875050:0.410875:0.875050:0.395119:0.543484:0.395119:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013143:0.005330:0.011392:0.009583:0.014239:0.005330:0.012604:0.006042:0.005330:0.010660:0.006388:0.010660:0.010660:0.005330:0.011738:0.012950:0.008409:0.018049:0.003848:0.005330
detected 95% of prostate cancers; :@0.543484:0.427160:0.872860:0.427160:0.872860:0.411404:0.543484:0.411404:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330:0.010660:0.010660:0.014913:0.005330:0.012604:0.006042:0.005330:0.013123:0.005700:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.005330
above this level very few prostate :@0.543484:0.443445:0.861865:0.443445:0.861865:0.427689:0.543484:0.427689:0.013143:0.013123:0.012604:0.010660:0.012508:0.005330:0.006523:0.011738:0.003848:0.007466:0.005330:0.003848:0.012508:0.010660:0.012508:0.003848:0.005330:0.010660:0.012508:0.005792:0.010314:0.005330:0.006042:0.012508:0.015990:0.005330:0.013123:0.005711:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330
cancers are diagnosed.:@0.543484:0.459730:0.766996:0.459730:0.766996:0.443974:0.543484:0.443974:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.013143:0.005707:0.012508:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.013181:0.005330
3:@0.766989:0.454058:0.773204:0.454058:0.773204:0.444872:0.766989:0.444872:0.006215
n   :@0.524242:0.472839:0.547050:0.472839:0.547050:0.464399:0.524242:0.464399:0.009762:0.003566:0.005914:0.003566
Screening :@0.543484:0.475958:0.642390:0.475958:0.642390:0.459924:0.543484:0.459924:0.010006:0.012315:0.006158:0.012315:0.012315:0.011545:0.004618:0.011545:0.012700:0.005388
– PSA, although very useful in :@0.642390:0.475958:0.914650:0.475958:0.914650:0.460202:0.642390:0.460202:0.009621:0.005330:0.011392:0.009583:0.014239:0.005330:0.005330:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005330:0.010660:0.012508:0.005792:0.010314:0.005330:0.011699:0.007466:0.012508:0.006042:0.011699:0.003848:0.003078:0.003848:0.011738:0.005330
 :@0.890627:0.470339:0.893735:0.470339:0.893735:0.461153:0.890627:0.461153:0.003107
diagnosis, is now challenged as it does :@0.543483:0.492243:0.908665:0.492243:0.908665:0.476487:0.543483:0.476487:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.005330:0.003848:0.007466:0.005330:0.011738:0.012604:0.015990:0.005330:0.012450:0.011738:0.013143:0.003848:0.003848:0.012508:0.011738:0.012950:0.012508:0.013181:0.005330:0.013143:0.007466:0.005330:0.003848:0.006523:0.005330:0.013181:0.012604:0.012508:0.007466:0.005330
not seem to reduce prostate cancer :@0.543483:0.508528:0.889696:0.508528:0.889696:0.492772:0.543483:0.492772:0.011738:0.012604:0.006523:0.005330:0.007466:0.012508:0.012508:0.018049:0.005330:0.006523:0.012604:0.005330:0.005688:0.012508:0.013181:0.011699:0.012450:0.012508:0.005330:0.013123:0.005707:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
mortality. If it does reduce mortality, :@0.543483:0.524813:0.881978:0.524813:0.881978:0.509057:0.543483:0.509057:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.005330:0.004349:0.006042:0.005330:0.003848:0.006523:0.005330:0.013181:0.012604:0.012508:0.007466:0.005330:0.005698:0.012508:0.013181:0.011699:0.012450:0.012508:0.005330:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.005330
the reduction is likely to be small. :@0.543483:0.541098:0.853601:0.541098:0.853601:0.525343:0.543483:0.525343:0.006523:0.011738:0.012508:0.005330:0.005703:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.003848:0.007466:0.005330:0.003848:0.003848:0.009660:0.012508:0.003848:0.010314:0.005330:0.006523:0.012604:0.005330:0.013123:0.012508:0.005330:0.007466:0.018049:0.013143:0.003848:0.003848:0.005330:0.005330
The European Randomised Study of :@0.543483:0.557384:0.880750:0.557384:0.880750:0.541628:0.543483:0.541628:0.008197:0.011738:0.012508:0.005330:0.010314:0.011699:0.005702:0.012604:0.013123:0.012508:0.013143:0.011738:0.005330:0.011680:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.009583:0.006523:0.011699:0.013181:0.010314:0.005330:0.012604:0.006042:0.005330
Prostate Cancer (ERSPC) concluded, :@0.543483:0.573669:0.893747:0.573669:0.893747:0.557913:0.543483:0.557913:0.011392:0.005709:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.007100:0.010314:0.011680:0.009583:0.011392:0.015644:0.007100:0.005330:0.012450:0.012604:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.013181:0.005330:0.005330
however, that PSA screening could :@0.543483:0.589954:0.873051:0.589954:0.873051:0.574198:0.543483:0.574198:0.011738:0.012604:0.015990:0.012508:0.010660:0.012508:0.003762:0.005330:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.011392:0.009583:0.014239:0.005330:0.007466:0.012450:0.005690:0.012508:0.012508:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.012604:0.011699:0.003848:0.013181:0.005330
reduce prostate cancer mortality. The :@0.543483:0.606239:0.902286:0.606239:0.902286:0.590483:0.543483:0.590483:0.005713:0.012508:0.013181:0.011699:0.012450:0.012508:0.005330:0.013123:0.005707:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.005330:0.008197:0.011738:0.012508:0.005330
Prostate, Lung, Colorectal and Ovarian :@0.543483:0.622524:0.913899:0.622524:0.913899:0.606768:0.543483:0.606768:0.011392:0.005709:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.005330:0.008890:0.011699:0.011738:0.012950:0.005330:0.005330:0.015644:0.012604:0.003848:0.012604:0.005682:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.013143:0.011738:0.013181:0.005330:0.016722:0.010660:0.013143:0.005792:0.003848:0.013143:0.011738:0.005330
Cancer Screening Trial (PLCO) showed :@0.543483:0.638809:0.909008:0.638809:0.909008:0.623053:0.543483:0.623053:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.009583:0.012450:0.005703:0.012508:0.012508:0.011738:0.003848:0.011738:0.012950:0.005330:0.007608:0.005792:0.003848:0.013143:0.003848:0.005330:0.007100:0.011392:0.008890:0.015644:0.016722:0.007100:0.005330:0.007466:0.011738:0.012604:0.015990:0.012508:0.013181:0.005330
no or very little reduction in prostate :@0.543483:0.655094:0.883325:0.655094:0.883325:0.639338:0.543483:0.639338:0.011738:0.012604:0.005330:0.012604:0.005792:0.005330:0.010660:0.012508:0.005792:0.010314:0.005330:0.003848:0.003848:0.006523:0.006523:0.003848:0.012508:0.005330:0.005690:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.003848:0.011738:0.005330:0.013123:0.005703:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330
cancer mortality.:@0.543483:0.671379:0.702868:0.671379:0.702868:0.655623:0.543483:0.655623:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330
4:@0.702854:0.665714:0.709069:0.665714:0.709069:0.656529:0.702854:0.656529:0.006215
n   :@0.524242:0.684496:0.547050:0.684496:0.547050:0.676055:0.524242:0.676055:0.009762:0.003566:0.005914:0.003566
Imaging :@0.543484:0.687615:0.626611:0.687615:0.626611:0.671581:0.543484:0.671581:0.005388:0.018088:0.012700:0.012700:0.004618:0.011545:0.012700:0.005388
– diagnostic work-up prior to a :@0.626611:0.687615:0.914651:0.687615:0.914651:0.671859:0.626611:0.671859:0.009621:0.005330:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.005330:0.015990:0.012604:0.005792:0.009660:0.006388:0.011699:0.013123:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.006523:0.012604:0.005330:0.013143:0.005330
decision on the treatment modality of :@0.543484:0.703900:0.901582:0.703900:0.901582:0.688144:0.543484:0.688144:0.013181:0.012508:0.012450:0.003848:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.005692:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.018049:0.012604:0.013181:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.012604:0.006042:0.005330
choice should include a detailed pelvic :@0.543484:0.720185:0.919192:0.720185:0.919192:0.704429:0.543484:0.704429:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.005330:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330:0.013143:0.005330:0.013181:0.012508:0.006523:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.013123:0.012508:0.003848:0.010660:0.003848:0.012450:0.005330
MRI to the risk factors (see below).:@0.543484:0.736470:0.859945:0.736470:0.859945:0.720714:0.543484:0.720714:0.017684:0.011680:0.004349:0.005330:0.006523:0.012604:0.005330:0.006523:0.011738:0.012508:0.005330:0.005792:0.003848:0.007466:0.009660:0.005330:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.007100:0.007466:0.012508:0.012508:0.005330:0.013123:0.012508:0.003848:0.012604:0.015990:0.007100:0.005330
PATHOPHYSIOLOGY:@0.524242:0.769668:0.747197:0.769668:0.747197:0.750071:0.524242:0.750071:0.013170:0.017404:0.009878:0.015993:0.019756:0.013170:0.015993:0.014581:0.012230:0.006585:0.019756:0.010348:0.019756:0.019756:0.014581
More than 95% of cancers of the prostate :@0.524242:0.788242:0.920506:0.788242:0.920506:0.772486:0.524242:0.772486:0.017684:0.012604:0.005707:0.012508:0.005984:0.006523:0.011738:0.013143:0.011738:0.005984:0.010660:0.010660:0.014913:0.005984:0.012604:0.006042:0.005973:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005975:0.012604:0.006042:0.005973:0.006523:0.011738:0.012508:0.005973:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330
are adenocarcinomas. Most tumours arise :@0.524242:0.804527:0.920476:0.804527:0.920476:0.788771:0.524242:0.788771:0.013143:0.005715:0.012508:0.004907:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005651:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.007466:0.005330:0.004907:0.017684:0.012604:0.007466:0.006523:0.004907:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.004907:0.013143:0.005792:0.003848:0.007466:0.012508:0.005330
in the peripheral zone of the prostate.:@0.524242:0.820812:0.875331:0.820812:0.875331:0.805056:0.524242:0.805056:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.013123:0.012508:0.005792:0.003848:0.013123:0.011738:0.012508:0.005792:0.013143:0.003848:0.005330:0.008178:0.012604:0.011738:0.012508:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.013123:0.005669:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330
GLEASON SCORE:@0.524242:0.853691:0.698706:0.853691:0.698706:0.835875:0.524242:0.835875:0.017960:0.009407:0.011118:0.015822:0.011118:0.017960:0.015822:0.005987:0.011118:0.016677:0.017960:0.012401:0.011118
Histological  grading is one of the most :@0.524242:0.871119:0.920493:0.871119:0.920493:0.855363:0.524242:0.855363:0.013143:0.003848:0.007466:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330:0.006150:0.012950:0.005792:0.013143:0.013181:0.003848:0.011738:0.012950:0.011468:0.003848:0.007466:0.011468:0.012604:0.011738:0.012508:0.011468:0.012604:0.006042:0.011468:0.006523:0.011738:0.012508:0.011468:0.018049:0.012604:0.007466:0.006523:0.005330
important  variables in prognosis determi-:@0.524242:0.887404:0.915145:0.887404:0.915145:0.871648:0.524242:0.871648:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.005330:0.003061:0.010660:0.013143:0.005792:0.003848:0.013143:0.013123:0.003848:0.012508:0.007466:0.008409:0.003848:0.011738:0.008409:0.013123:0.005715:0.012604:0.012950:0.011738:0.012590:0.007466:0.003848:0.007466:0.008409:0.013181:0.012508:0.006523:0.012508:0.006317:0.018049:0.003848:0.006388
nation. Five distinct patterns, from well- to :@0.524242:0.903689:0.920481:0.903689:0.920481:0.887933:0.524242:0.887933:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006225:0.009333:0.003848:0.010660:0.012508:0.006235:0.013181:0.003848:0.007466:0.006523:0.003848:0.011738:0.012450:0.006523:0.006235:0.013123:0.013143:0.006523:0.006523:0.012508:0.006190:0.011738:0.007466:0.005330:0.006235:0.006042:0.005711:0.012604:0.018049:0.006235:0.015990:0.012508:0.003848:0.003848:0.006388:0.006235:0.006523:0.012604:0.005330
poorly-differentiated, were described in :@0.524242:0.919974:0.920472:0.919974:0.920472:0.904218:0.524242:0.904218:0.013123:0.012604:0.012604:0.005792:0.003848:0.010314:0.006388:0.013181:0.003848:0.006100:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.012392:0.015990:0.012508:0.005711:0.012508:0.012392:0.013181:0.012508:0.007466:0.012450:0.005792:0.003848:0.013123:0.012508:0.013181:0.012392:0.003848:0.011738:0.005330
the original Gleason grading scale. The :@0.524242:0.936259:0.920481:0.936259:0.920481:0.920503:0.524242:0.920503:0.006523:0.011738:0.012508:0.010699:0.012604:0.005792:0.003848:0.012950:0.003848:0.011738:0.013143:0.003848:0.010699:0.016779:0.003848:0.012508:0.013143:0.007466:0.012604:0.011738:0.010699:0.012950:0.005792:0.013143:0.013181:0.003848:0.011738:0.012950:0.010699:0.007466:0.012450:0.013143:0.003848:0.012508:0.005330:0.010699:0.008197:0.011738:0.012508:0.005330
Prostate Cancer:@0.084848:0.111850:0.417528:0.111850:0.417528:0.076219:0.084848:0.076219:0.023946:0.013683:0.027367:0.018815:0.012828:0.028222:0.012828:0.027367:0.011973:0.033354:0.028222:0.025657:0.027367:0.027367:0.013683